ABSTRACT
PAX3/7 fusion-negative rhabdomyosarcoma (FN-RMS) is a childhood mesodermal lineage malignancy with a poor prognosis for metastatic or relapsed cases. Limited understanding of advanced FN-RMS is partially attributed to the absence of sequential invasion and dissemination events and the challenge in studying cell behavior, using, for example, non-invasive intravital microscopy (IVM), in currently used xenograft models. Here, we developed an orthotopic tongue xenograft model of FN-RMS to study cell behavior and the molecular basis of invasion and metastasis using IVM. FN-RMS cells are retained in the tongue and invade locally into muscle mysial spaces and vascular lumen, with evidence of hematogenous dissemination to the lungs and lymphatic dissemination to lymph nodes. Using IVM of tongue xenografts reveals shifts in cellular phenotype, migration to blood and lymphatic vessels, and lymphatic intravasation. Insight from this model into tumor invasion and metastasis at the tissue, cellular, and subcellular level can guide new therapeutic avenues for advanced FN-RMS.
Subject(s)
Neoplasm Invasiveness , Rhabdomyosarcoma , Tongue Neoplasms , Animals , Rhabdomyosarcoma/pathology , Rhabdomyosarcoma/secondary , Humans , Mice , Tongue Neoplasms/pathology , Cell Line, Tumor , Neoplasm Metastasis/pathology , Heterografts , Tongue/pathology , Cell MovementABSTRACT
Over the last decade, the development of next-generation sequencing techniques has led to the molecular dismantlement of adult and pediatric sarcoma, with the identification of multiple gene fusions associated with specific subtypes and currently integrated into diagnostic classifications. In this report, we describe and discuss the identification of a novel EWSR1-UBP1 gene fusion in an adult patient presenting with multi-metastatic sarcoma. Extensive pathological, transcriptomic, and genomic characterization of this tumor in comparison with a cohort of different subtypes of pediatric and adult sarcoma revealed that this fusion represents a novel variant of spindle cell rhabdomyosarcoma with features of TFCP2-rearranged subfamily.
Subject(s)
DNA-Binding Proteins/genetics , Liver Neoplasms/secondary , Lung Neoplasms/genetics , Oncogene Proteins, Fusion/genetics , RNA-Binding Protein EWS/genetics , Rhabdomyosarcoma/genetics , Transcription Factors/genetics , Bone Neoplasms/secondary , Female , Humans , Liver Neoplasms/genetics , Lung Neoplasms/pathology , Middle Aged , Rhabdomyosarcoma/classification , Rhabdomyosarcoma/pathology , Rhabdomyosarcoma/secondary , Skin Neoplasms/secondaryABSTRACT
BACKGROUND/OBJECTIVES: The primary aim of this study was to analyse and evaluate the impact of different local treatments on the pattern of relapse in children with primary head and neck non-parameningeal (HNnPM) rhabdomyosarcoma (RMS), treated in the European paediatric Soft tissue sarcoma Study Group (EpSSG) RMS2005 study. The secondary aim was to assess whether current risk stratification is valid for this specific site. DESIGN/METHODS: This study includes all patients with localised HNnPM RMS enrolled in the RMS2005 study between 2005 and 2016. Treatment comprised chemotherapy adapted to risk group, with local surgery and/or radiation therapy. The main outcome measures were event-free survival (EFS) and overall survival (OS). RESULTS: A total of 165 patients were identified; the median age was 6.4 years (range, 0.1-25). The most common tumour sites were cheek/chin (22%) and nasal ala/nasolabial fold (20%). Histology was unfavourable for 40%, and regional nodal involvement present in 26%. Local therapy included surgery (58%) and/or radiotherapy (72%) to primary tumour and/or regional lymph nodes. After a median follow-up of 66 months (range, 6-158), 42 patients experienced an event, and 17 are still alive. Tumour events were frequent in oral primary (36%), parotid site (26%), cheek/chin (24%), and nasal ala/nasolabial fold (24%) and included locoregional failure in 84% of cases. The 5-year EFS and OS were 75% (95% confidence interval [CI]: 67.3-81.2) and 84.9% (95% CI: 77.5-89.7), respectively. Favourable histology was associated with a better EFS (82.3% versus 64.6%; p = 0.02) and nodal spread with a worse OS (88.6% versus 76.1%; p = 0.04). Different sublocations within the HNnPM primary did not have significant impact on outcome. CONCLUSION: Locoregional relapse/progression is the main tumour failure event in this site. Despite frequent unfavourable risk factors, HNnPM RMS remains a favourable location in the context of a risk-adapted strategy.
Subject(s)
Head and Neck Neoplasms/therapy , Neoplasm Recurrence, Local , Rhabdomyosarcoma/therapy , Adolescent , Adult , Age Factors , Argentina , Brazil , Child , Child, Preschool , Disease Progression , Europe , Female , Head and Neck Neoplasms/mortality , Head and Neck Neoplasms/pathology , Humans , Infant , Israel , Lymphatic Metastasis , Male , Progression-Free Survival , Prospective Studies , Rhabdomyosarcoma/mortality , Rhabdomyosarcoma/secondary , Risk Assessment , Risk Factors , Time Factors , Young AdultABSTRACT
VGLL2-rearranged rhabdomyosarcomas (RMS) are rare low-grade tumors with only favorable outcomes reported to date. We describe 4 patients with VGLL2-rearranged RMS confirmed by molecular studies, who experienced local progression and distant metastases, including 2 with fatal outcomes. Tumors were diagnosed at birth (n=3) or at 12 months of age (n=1), and were all localized at initial diagnosis, but unresectable and therefore managed with chemotherapy and surveillance. Metastatic progression occurred from 1 to 8 years from diagnosis (median, 3.5 y). Three patients experienced multimetastatic spread and one showed an isolated adrenal metastasis. At initial diagnosis, 3 tumors displaying bland morphology were misdiagnosed as fibromatosis or infantile fibrosarcoma and initially managed as such, while 1 was a high-grade sarcoma. At relapse, 3 tumors showed high-grade morphology, while 1 retained a low-grade phenotype. Low-grade primary tumors showed only very focal positivity for desmin, myogenin, and/or MyoD1, while high-grade tumors were heterogenously or diffusely positive. Whole-exome sequencing, performed on primary and relapse samples for 3 patients, showed increased genomic instability and additional genomic alterations (eg, TP53, CDKN2A/B, FGFR4) at relapse, but no recurrent events. RNA sequencing confirmed that high-grade tumors retained VGLL2 fusion transcripts and transcriptomic profiles consistent with VGLL2-rearranged RMS. High-grade samples showed a high expression of genes encoding cell cycle proteins, desmin, and some developmental factors. These 4 cases with distinct medical history imply the importance of complete surgical resection, and suggest that RMS-type chemotherapy should be considered in unresectable cases, given the risk of high-grade transformation. They also emphasize the importance of correct initial diagnosis.
Subject(s)
Biomarkers, Tumor/genetics , Gene Rearrangement , Muscle Proteins/genetics , Rhabdomyosarcoma/genetics , Transcription Factors/genetics , Belgium , Disease Progression , Fatal Outcome , Female , France , Genetic Predisposition to Disease , Humans , Immunohistochemistry , Infant , Infant, Newborn , Male , Neoplasm Grading , Phenotype , RNA-Seq , Rhabdomyosarcoma/diagnostic imaging , Rhabdomyosarcoma/drug therapy , Rhabdomyosarcoma/secondary , Treatment Outcome , Exome SequencingABSTRACT
OBJECTIVE. The purpose of this article is to review currently available and emerging techniques for pediatric lung MRI for general radiologists. CONCLUSION. MRI is a radiation-free alternative to CT, and clearly understanding the strengths and limitations of established and emerging techniques of pediatric lung MRI can allow practitioners to select and combine the optimal techniques, apply them in clinical practice, and potentially improve early diagnostic accuracy and patient management.
Subject(s)
Lung Diseases/diagnostic imaging , Lung/diagnostic imaging , Magnetic Resonance Imaging/methods , Adolescent , Artifacts , Breath Holding , Child , Child, Preschool , Cystic Fibrosis/diagnostic imaging , Female , Fourier Analysis , Humans , Infant , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/secondary , Magnetic Resonance Imaging/trends , Male , Pulmonary Atelectasis/prevention & control , Rhabdomyosarcoma/diagnostic imaging , Rhabdomyosarcoma/secondaryABSTRACT
Most cases of malignancies appear to be sporadic, but some syndromes are associated with malignancies with germline variants. Herein, a child with an unusual association of oncocytic variant adrenocortical carcinoma (ACC) and rhabdomyosarcoma (RMS) was presented. An 18-month-old-boy was admitted with virilization of the genital area, penis enlargement and erection, which had begun six months earlier. Serum total testosterone (457 ng/dL; NR <10), androstenedione (3.35 ng/mL; NR <0.5) and dehydroepiandrosterone-SO4 (206 mcg/dL; NR<35) were above the normal ranges. Right adrenal mass was detected. After adrenalectomy, histopathological examination revealed an oncocytic variant ACC. Three-month after surgery, he then presented with 6x8 cm sized swelling of the left leg. Histopathological examination revealed embryonal RMS. Testing for tumor protein (TP53) variant by DNA sequence analysis was positive; however; fluorescence in situ hybridization analysis was negative. After chemotherapy and local radiotherapy, the patient is in good condition without tumor recurrence. Only about one-third of these tumors have a variant of TP53. This status also applies to other genetic variants related to cancer. However, a significant association of malignancies strongly suggests a problem in tumor suppressor genes or new variants. Another as yet unidentified suppressor gene may also be present and effective in this locus. The occurrence of ACC as a part of a syndrome and positive family history of malignancies in patients are clinically important. These patients and their families should be scanned for genetic abnormalities. The patient with ACC should be followed-up carefully for other tumors to detect malignancy early.
Subject(s)
Adenoma, Oxyphilic/diagnosis , Adrenocortical Carcinoma/diagnosis , Rhabdomyosarcoma/diagnosis , Adenoma, Oxyphilic/pathology , Adrenocortical Carcinoma/complications , Adrenocortical Carcinoma/pathology , Humans , Infant , Male , Neoplasms, Second Primary , Puberty, Precocious/diagnosis , Puberty, Precocious/etiology , Rhabdomyosarcoma/complications , Rhabdomyosarcoma/secondaryABSTRACT
BACKGROUND: Rhabdomyosarcoma (RMS) is a highly malignant soft tissue sarcoma (STS), usually of adults, displaying skeletal muscle differentiation. STS principally metastasize to the lungs with more than 50% of metastatic patients presenting with isolated pulmonary metastasis. Paradoxically, the majority of drugs prescribed to treat RMS are associated with multidrug resistance. CASE REPORT: We report the case of a 53 year-old patient who developed three synchronous chemoresistant lung metastasis from pleomorphic RMS. Considering the poor prognosis, the patient's preference and the chemoresistance of her lung metastasis, we decided to perform two consecutive stereotactic body radiotherapy (SBRT) on two of these three lesions. DISCUSSION: Initially, the patient was referred to our institute with a painful mass in the anterior part of the left thigh increasing in volume for 3 months. Biopsy revealed a high-grade pleomorphic RMS. The cancer being staged IB, she had neoadjuvant radiotherapy. After complete surgical excision, pathology examination revealed a 6 cm Grade II pleomorphic RMS, with clear margins. Six months later, she developed three synchronous lung metastases. She got 4 courses of doxorubicin-ifosfamide which were poorly supported. After two courses, a heterogeneous (morphological and metabolic) response was observed, hence SBRT was delivered with a Biologically Equivalent Dose (α/ß10)> 100 Gray on the two more chemoresistant lesions. This SBRT was very well tolerated, no side effects were reported. The patient remained alive and achieved a complete response of these three metastases, which sustains after more than 3 years. CONCLUSION: Early recognition and proper management of these oligometastatic patients may lead to motivating results in a poor prognosis disease.
Subject(s)
Lung Neoplasms/therapy , Radiosurgery , Rhabdomyosarcoma/therapy , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Doxorubicin/pharmacology , Doxorubicin/therapeutic use , Drug Resistance, Neoplasm , Female , Humans , Ifosfamide/pharmacology , Ifosfamide/therapeutic use , Lung Neoplasms/diagnosis , Lung Neoplasms/mortality , Lung Neoplasms/secondary , Middle Aged , Prognosis , Rhabdomyosarcoma/diagnosis , Rhabdomyosarcoma/mortality , Rhabdomyosarcoma/secondary , Survival Rate , Thigh , Treatment OutcomeABSTRACT
Refractory metastatic rhabdomyosarcoma is largely incurable. Here we analyze the response of a child with refractory bone marrow metastatic rhabdomyosarcoma to autologous HER2 CAR T cells. Three cycles of HER2 CAR T cells given after lymphodepleting chemotherapy induces remission which is consolidated with four more CAR T-cell infusions without lymphodepletion. Longitudinal immune-monitoring reveals remodeling of the T-cell receptor repertoire with immunodominant clones and serum autoantibodies reactive to oncogenic signaling pathway proteins. The disease relapses in the bone marrow at six months off-therapy. A second remission is achieved after one cycle of lymphodepletion and HER2 CAR T cells. Response consolidation with additional CAR T-cell infusions includes pembrolizumab to improve their efficacy. The patient described here is a participant in an ongoing phase I trial (NCT00902044; active, not recruiting), and is 20 months off T-cell infusions with no detectable disease at the time of this report.
Subject(s)
Immunotherapy, Adoptive/methods , Muscle Neoplasms/therapy , Neoplasm Recurrence, Local/therapy , Receptor, ErbB-2/immunology , Rhabdomyosarcoma/therapy , T-Lymphocytes/transplantation , Biopsy , Bone Marrow/pathology , Child , Clinical Trials, Phase I as Topic , Humans , Male , Muscle Neoplasms/immunology , Muscle Neoplasms/pathology , Neoplasm Recurrence, Local/immunology , Receptors, Chimeric Antigen/immunology , Remission Induction/methods , Rhabdomyosarcoma/immunology , Rhabdomyosarcoma/secondary , T-Lymphocytes/immunology , T-Lymphocytes/metabolism , Transplantation, Autologous/methods , Treatment OutcomeABSTRACT
OBJECTIVE: Vulvar cancers account for 5% of all gynecologic malignancies; only 1%-3% of those vulvar cancers are primary vulvar sarcomas. Given the rarity of vulvar sarcomas, outcome data specific to histopathologic subtypes are sparse. The aim of this study was to identify clinical and pathologic factors of primary vulvar sarcomas that are associated with survival and may inform treatment decisions. METHODS: The Surveillance, Epidemiology, and End Results (SEER) database was searched for women diagnosed with vulvar sarcoma between 1973 and 2018. We identified 315 patients and reviewed their demographic, clinicopathologic, surgical, and survival information. Statistical analyses included χ2 and t-tests, Kaplan-Meier survival, and Cox regression analyses. RESULTS: The most common histopathologies of vulvar sarcomas were dermatofibrosarcomas (85/315, 27%) and leiomyosarcomas (72/315, 22.9%). Rhabdomyosarcomas (18/315, 5.7%), liposarcomas (16/315, 5.1%), and malignant fibrous histiocytomas (16/315, 5.1%) were less frequent. The majority of patients underwent surgery (292/315, 92.7%), which included lymph node dissections in 21.6% (63/292). Survival and lymph node involvement varied significantly with histologic subtype. The 5-year disease-specific survival for dermatofibrosarcomas, liposarcomas, and fibrosarcomas was 100% and only 60.3% and 62.5% for malignant fibrous histiocytomas and rhabdomyosarcomas, respectively. None of the patients with (dermato)fibrosarcomas, liposarcomas, or leiomyosarcomas had positive lymph nodes, in contrast to rhabdomyosarcomas and malignant fibrous histiocytomas with 77.8% and 40% positive lymph nodes, respectively. The 5-year disease-specific survival for women with positive lymph nodes was 0%. CONCLUSIONS: Vulvar sarcomas are heterogeneous with survival highly dependent on the histopathologic subtype. While surgical excision is the mainstay of treatment for all vulvar sarcomas, staging lymphadenectomy should be deferred for (dermato)fibrosarcomas, liposarcomas, and leiomyosarcomas as there were no cases of lymph nodes metastases.
Subject(s)
Sarcoma/mortality , Sarcoma/secondary , Vulvar Neoplasms/mortality , Vulvar Neoplasms/pathology , Antineoplastic Agents/therapeutic use , Dermatofibrosarcoma/mortality , Dermatofibrosarcoma/secondary , Female , Histiocytoma, Malignant Fibrous/mortality , Histiocytoma, Malignant Fibrous/secondary , Humans , Kaplan-Meier Estimate , Leiomyosarcoma/mortality , Leiomyosarcoma/secondary , Liposarcoma/mortality , Liposarcoma/secondary , Lymph Node Excision , Lymphatic Metastasis , Middle Aged , Proportional Hazards Models , Radiotherapy , Rhabdomyosarcoma/mortality , Rhabdomyosarcoma/secondary , SEER Program , Sarcoma/therapy , Survival Rate , United States/epidemiology , Vulvar Neoplasms/therapy , VulvectomyABSTRACT
The WHO Classification of Tumors of Soft Tissue and Bone divides rhabdomyosarcoma (RMS) into alveolar, embryonal, pleomorphic, and spindle cell/sclerosing types. Advances in molecular diagnostics have allowed for further refinement of RMS classification including the identification of new subtypes. Very rare RMS with epithelioid and spindle cell morphology, female predominance, marked osseous predilection, ALK expression, EWSR1/FUS-TFCP2 gene fusions, and highly aggressive clinical behavior have recently been recognized with only 23 cases reported in the English language literature. Herein, we report two additional cases with detailed clinicopathologic description and molecular confirmation. In brief, two young women presented each with a primary bone tumor-one with a frontal bone tumor and another with an osseous pelvic tumor. Both tumors showed epithelioid to spindle cell morphology, ALK expression, and EWSR1/FUS-TFCP2 gene fusions. Both patients died of disease less than 17 months from diagnosis despite administration of multiple lines of aggressive treatment. In addition, we review the literature and discuss differential diagnostic and potential treatment considerations.
Subject(s)
Biomarkers, Tumor/genetics , DNA-Binding Proteins/genetics , Gene Fusion , Pelvic Neoplasms/genetics , RNA-Binding Protein EWS/genetics , RNA-Binding Protein FUS/genetics , Rhabdomyosarcoma/genetics , Skull Neoplasms/genetics , Transcription Factors/genetics , Adult , Disease Progression , Epithelioid Cells/pathology , Fatal Outcome , Female , Frontal Bone/pathology , Genetic Predisposition to Disease , Humans , Pelvic Neoplasms/diagnostic imaging , Pelvic Neoplasms/pathology , Pelvic Neoplasms/therapy , Phenotype , Rhabdomyosarcoma/diagnostic imaging , Rhabdomyosarcoma/secondary , Rhabdomyosarcoma/therapy , Skull Neoplasms/diagnostic imaging , Skull Neoplasms/pathology , Skull Neoplasms/therapy , Young AdultABSTRACT
BACKGROUND: Rhabdomyosarcoma is a rare malignant tumor originating from striated muscle cells. It accounts for only 3% of all soft tissue sarcomas in adults, and its metastases can also reach the central nervous system. Only sporadic cases of primary brain rhabdomyosarcoma (PBRMS) have been reported so far. CASE DESCRIPTION: We discuss the atypical presentation and diagnostic challenge of PBRMS in a 65-year-old man. He presented with a 3-day history of progressive right hemiparesis caused by an unspecific left frontoparietal heterogeneously enhancing lesion. Total body computed tomography and positron emission tomography scans performed at baseline did not reveal other secondarisms. The patient underwent radical excision of the lesion, which allowed to establish the diagnosis, with immunohistochemical staining positive for desmin and myogenin. Stereotactic radiotherapy guaranteed local disease control; nonetheless, the patient also required adjuvant chemotherapy when he developed large right lung metastases 6 months postoperatively. CONCLUSIONS: PBRMS can be hardly distinguished from other malignant brain tumors during preoperative radiologic workup; only histology can raise the suspicion of primary or metastatic rhabdomyosarcoma, depending on the presence of other distant lesions. Our review of the literature demonstrates that prognosis is poor: 44% of patients die within 1 year from diagnosis. Overall, survival seems to correlate with radical resection, tolerance of stereotactic or if necessary full neuraxis radiotherapy, and adjuvant chemotherapy. Given the high relapse rate, close monitoring and restaging are imperative.
Subject(s)
Brain Neoplasms/diagnosis , Brain Neoplasms/pathology , Lung Neoplasms/secondary , Rhabdomyosarcoma/diagnosis , Rhabdomyosarcoma/secondary , Aged , Humans , MaleABSTRACT
Paratesticular Rhabdomyosarcoma accounts for 7 to 11% of pediatric rhabdomyosarcomas. Children older than 10 years have a worse event-free survival (69 to 80% vs. 87 to 92%) than children younger than 10 years. In this location, the relapses are essentially in the retroperitoneal lymph nodes and are often fatal. In European protocols, the assessment of the retroperitoneal lymph nodes at diagnosis is made by imaging whereas it is performed by retroperitoneal lymph node dissection in the American protocols. This method has been proved to improve event-free survival in the group of patient older than 10 years with a tumour bigger than 5cm. In the next European protocol, when nodes will be enlarged a surgical biopsy will be performed, this will be irrespective of age or size, and when no nodes will be enlarged in patients older than 10 years, retroperitoneal lymph node assessment will be performed. Other techniques of lymph nodes assessment will be tested like sentinel node biopsies or PET-scan.
Subject(s)
Lymphatic Metastasis/pathology , Rhabdomyosarcoma/secondary , Testicular Neoplasms/pathology , Child , Disease-Free Survival , Humans , Lymph Node Excision , Male , Retroperitoneal Space , Rhabdomyosarcoma/surgery , Testicular Neoplasms/surgeryABSTRACT
OBJECTIVES: Rhabdomyosarcoma (RMS) involving the spine is rare. The aim of the present study is to explore the clinicopathological features, surgical treatments and outcomes of this rare disease. PATIENTS AND METHODS: Eleven patients with spinal RMS who received surgery in our institution between 2012 and 2018 were retrospectively investigated. The literature on spinal RMS was also reviewed. RESULTS: Our study consisted of 7 cases of primary RMS and 4 cases of metastatic RMS. Seven primary and one metastatic spinal RMS received radical resection, the remaining three metastatic patients received palliative resection. Eight patients died with a median survival time of 8 months. The mean value of Ki-67 positivity was 48.2 %. Literature review revealed a total of 22 previously reported cases. 54.5 % of the pooled cases of the 33 patients were under the age of 18. Of the 20 patients with primary spinal RMS, 9 cases were diagnosed as embryonal, while 6 of the 13 metastatic patients were diagnosed as alveolar. Multiple modalities, including surgery and concurrent adjuvant therapy were performed in 19 patients. The median overall survival (OS) for 28 patients with detailed follow-up information was 10 months. Radical resection offered a significant longer median OS than non-radical resection (18 vs. 6 months, p = 0.027). CONCLUSION: Spinal RMS mainly affects young patients. The embryonal form and alveolar form is the most frequent subtype for primary and metastatic spinal RMS respectively. Spinal RMS is highly aggressive with dismal prognosis. Multimodality therapies are the mainstay of treatment. Radical resection is strongly recommended in eligible patients.
Subject(s)
Neurosurgical Procedures , Rhabdomyosarcoma, Alveolar/surgery , Rhabdomyosarcoma, Embryonal/surgery , Spinal Neoplasms/surgery , Adolescent , Adult , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Buttocks , Chemoradiotherapy, Adjuvant , Chemotherapy, Adjuvant , Child, Preschool , Cohort Studies , Cyclophosphamide/therapeutic use , Dactinomycin/therapeutic use , Female , Humans , Karnofsky Performance Status , Male , Middle Aged , Operative Time , Palliative Care , Prostatic Neoplasms/pathology , Retroperitoneal Neoplasms/pathology , Rhabdomyosarcoma/diagnostic imaging , Rhabdomyosarcoma/pathology , Rhabdomyosarcoma/secondary , Rhabdomyosarcoma/surgery , Rhabdomyosarcoma, Alveolar/diagnostic imaging , Rhabdomyosarcoma, Alveolar/pathology , Rhabdomyosarcoma, Alveolar/secondary , Rhabdomyosarcoma, Embryonal/diagnostic imaging , Rhabdomyosarcoma, Embryonal/pathology , Rhabdomyosarcoma, Embryonal/secondary , Spinal Neoplasms/diagnostic imaging , Spinal Neoplasms/pathology , Spinal Neoplasms/secondary , Survival Rate , Vincristine/therapeutic use , Vulvar Neoplasms/pathology , Young AdultABSTRACT
Primary rhabdomyosarcoma of tunica vaginalis is very rare. We report a case of a 15-year-old man presenting as hydrocele. Pre-operatively, no masses were detected by ultrasonography. Hydrocelectomy was performed. At surgery, a 0.8 cm polypoid nodule and diffusely thickened tunica were found. Pathologic examination finally revealed rhabdomyosarcoma. A PET-CT was then performed and indicated scrotal implantation metastasis. The patient underwent radical inguinal orchiectomy and was treated with chemotherapy and radiotherapy after surgery. At 12 months of follow-up, he remained disease-free.
Subject(s)
Rhabdomyosarcoma/diagnosis , Scrotum/pathology , Testicular Hydrocele/diagnosis , Testicular Neoplasms/diagnosis , Testis/pathology , Adolescent , Chemoradiotherapy, Adjuvant , Diagnostic Errors , Humans , Male , Orchiectomy , Rhabdomyosarcoma/secondary , Rhabdomyosarcoma/therapy , Scrotum/diagnostic imaging , Scrotum/surgery , Testicular Neoplasms/pathology , Testicular Neoplasms/therapy , Testis/diagnostic imaging , Testis/surgery , Treatment OutcomeABSTRACT
INTRODUCTION: Paediatric soft tissue sarcoma treatments and outcomes have improved significantly in the last few decades. However, a significant number of patients still succumb to the disease. In low-middle income countries there are dual problems of advanced disease at presentation and financial burden leading to poor compliance to therapy. Hence, we designed a low-cost oral metronomic chemotherapy protocol for these patients and studied the responses and toxicities to therapy in a tertiary referral hospital. PATIENTS AND METHODS: This is retrospective, single institutional, observational study. We retrospectively reviewed data of patients with relapsed, refractory or metastatic soft tissue sarcoma (STS) [ Ewing Sarcoma (ES); Rhabdomyosarcoma (RMS) or other STS] who were treated with the metronomic protocol of oral Tamoxifen, Etoposide and Cyclophosphamide (TEC) during the period April 1998 to September 2013, at the Tata Memorial Hospital, Parel, Mumbai. Patients with ES and RMS were primarily treated on our Institutional protocols. The patients included in the analysis were those who had relapsed after the primary protocols and then treated with metronomic TEC protocol; or those with primary refractory or metastatic disease (RMS, ES) and received metronomic TEC therapy. RESULTS: 49 patients were enrolled. Among the 49 patients, 32 were diagnosed ES, 13 RMS and 4 other STS. For the whole cohort response rates (RR) were 59% and clinical benefit rate (CBR) was 79%. Patients in the study were grouped into the following subgroups. Systemic recurrent/relapsed disease (N=24), metastatic disease at presentation (N=15) and local disease (refractory/recurrent) (N=10). None of the patients required blood or platelet support or admission for supportive care. The PFS for the above groups were 16.8 months, 12.5 months and 126.68 months respectively. This compares favorably with other historical cohorts in a similar setting. CONCLUSIONS: This study provides a preliminary evidence efficacy and tolerability of metronomic chemotherapy in poor risk ES and RMS. It also demonstrates that with this low-cost low risk treatment few patients could go into long term remissions despite high disease burden.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Drug Resistance, Neoplasm , Neoplasm Recurrence, Local/mortality , Rhabdomyosarcoma/mortality , Salvage Therapy , Sarcoma, Ewing/mortality , Sarcoma/mortality , Administration, Metronomic , Adolescent , Adult , Bone Neoplasms/drug therapy , Bone Neoplasms/mortality , Bone Neoplasms/pathology , Child , Child, Preschool , Cyclophosphamide/administration & dosage , Etoposide/administration & dosage , Female , Follow-Up Studies , Humans , Lymphatic Metastasis , Male , Middle Aged , Neoplasm Recurrence, Local/drug therapy , Neoplasm Recurrence, Local/pathology , Prognosis , Retrospective Studies , Rhabdomyosarcoma/drug therapy , Rhabdomyosarcoma/secondary , Sarcoma/drug therapy , Sarcoma/secondary , Sarcoma, Ewing/drug therapy , Sarcoma, Ewing/secondary , Survival Rate , Tamoxifen/administration & dosage , Young AdultABSTRACT
BACKGROUND: Rhabdomyosarcoma (RMS), especially primary pulmonary RMS, is an extremely rare type of soft tissue sarcoma in adults. Small bowel is an uncommon site for metastases. CASE PRESENTATION: This report described an unusual case of jejunum metastasis from primary pulmonary RMS causing intussusception in a 75-year-old man. The patient consulted for 2 weeks of continuous dyspnea. Chest computed tomography (CT) demonstrated a large mass involving the left lower lobe. Transthoracic biopsy confirmed the existence of pleomorphic RMS. Immunohistochemical studies showed positive findings about desmin and MyoD1. The results of gastroscopy, colonoscopy and abdominal CT were all negative. Positron emission tomography/CT demonstrated a fluorodeoxyglucose-reactive large lesion in the left lower lobe without metastatic lesions. The patient received synchronous chemoradiotherapy. After 9 months, the patient presented with intermittent upper abdominal pain with nausea and vomiting. CT showed small bowel dilatation secondary to intussusception. The patient subsequently received laparotomy, and the intussuscepted small bowel segment was resected. Histological examination revealed pleomorphic RMS involving the mucosa, submucosa, and muscular tissues. CONCLUSIONS: RMS is highly aggressive and metastatic. The metastatic disease can rapidly progress to cause subsequent complications. The possibility of small bowel metastasis should be considered, although it is extremely rare.
Subject(s)
Intussusception/etiology , Jejunal Neoplasms/complications , Lung Neoplasms/pathology , Rhabdomyosarcoma/complications , Aged , Humans , Jejunal Neoplasms/secondary , Male , Rhabdomyosarcoma/secondaryABSTRACT
Undifferentiated sarcoma has been hypothesized as an intermediate step in the progression of malignant melanoma to rhabdomyosarcoma. The current report describes a new case of rhabdomyosarcomatous transformation in a malignant melanoma and documents the temporal progression of the malignant melanoma to rhabdomyosarcoma in different metastatic sites via undifferentiated sarcoma. A 65-year-old female with a past medical history of malignant melanoma presented with a new lung mass. A core biopsy revealed a malignant spindle cell neoplasm that was negative for all melanocytic markers, suggesting the possibility of a primary pulmonary sarcomatoid carcinoma or sarcoma. The subsequent lobectomy demonstrated an undifferentiated spindle cell neoplasm with areas of rhabdomyoblastic differentiation. Review of the skin lesion and lymph nodes confirmed the diagnosis of the primary cutaneous malignant melanoma, but also revealed that the nodal metastases had largely transformed into an undifferentiated sarcoma with similar morphology as the spindle cell neoplasm in the lung. Molecular studies demonstrated an identical BRAFV600E mutation in both the primary malignant melanoma and the lung tumor. Interestingly, the metastatic malignant melanoma with rhabdomyosarcomatous transformation was the single metastasis resistant to anti-BRAF therapy, whereas other metastases displayed dramatic clinical responses. The case report provides further supportive evidence that undifferentiated sarcoma is an intermediate step in the progression of malignant melanoma to rhabdomyosarcoma. Pathologists should be aware of this phenomenon as proper documentation of an undifferentiated sarcoma or newly acquired phenotypic variations in a malignant melanoma could considerably improve diagnostic accuracy and therapeutic management of subsequent recurrences.
Subject(s)
Lung Neoplasms/diagnosis , Lung/pathology , Melanoma/diagnosis , Rhabdomyosarcoma/diagnosis , Skin Neoplasms/diagnosis , Aged , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Azetidines/pharmacology , Azetidines/therapeutic use , Biomarkers, Tumor/antagonists & inhibitors , Biomarkers, Tumor/genetics , Cell Transformation, Neoplastic/genetics , Diagnosis, Differential , Disease Progression , Drug Resistance, Neoplasm/genetics , Female , Humans , Lung/surgery , Lung Neoplasms/secondary , Lung Neoplasms/therapy , Melanoma/secondary , Melanoma/therapy , Neoadjuvant Therapy/methods , Piperidines/pharmacology , Piperidines/therapeutic use , Pneumonectomy , Proto-Oncogene Proteins B-raf/antagonists & inhibitors , Proto-Oncogene Proteins B-raf/genetics , Rhabdomyosarcoma/secondary , Rhabdomyosarcoma/therapy , Skin/pathology , Skin Neoplasms/drug therapy , Skin Neoplasms/pathology , Vemurafenib/pharmacology , Vemurafenib/therapeutic useABSTRACT
PURPOSE: To evaluate the clinical significance of indeterminate pulmonary nodules at diagnosis (defined as ≤ 4 pulmonary nodules < 5 mm or 1 nodule measuring ≥ 5 and < 10 mm) in patients with pediatric rhabdomyosarcoma (RMS). PATIENTS AND METHODS: We selected patients with supposed nonmetastatic RMS treated in large pediatric oncology centers in the United Kingdom, France, Italy, and the Netherlands, who were enrolled in the European Soft Tissue Sarcoma Study Group (E pSSG) RMS 2005 study. Patients included in the current study received a diagnosis between September 2005 and December 2013, and had chest computed tomography scans available for review that were done at time of diagnosis. Local radiologists were asked to review the chest computed tomography scans for the presence of pulmonary nodules and to record their findings on a standardized case report form. In the E pSSG RMS 2005 Study, patients with indeterminate pulmonary nodules were treated identically to patients without pulmonary nodules, enabling us to compare event-free survival and overall survival between groups by log-rank test. RESULTS: In total, 316 patients were included; 67 patients (21.2%) had indeterminate pulmonary nodules on imaging and 249 patients (78.8%) had no pulmonary nodules evident at diagnosis. Median follow-up for survivors (n = 258) was 75.1 months; respective 5-year event-free survival and overall survival rates (95% CI) were 77.0% (64.8% to 85.5%) and 82.0% (69.7% to 89.6%) for patients with indeterminate nodules and 73.2% (67.1% to 78.3%) and 80.8% (75.1% to 85.3%) for patients without nodules at diagnosis ( P = .68 and .76, respectively). CONCLUSION: Our study demonstrated that indeterminate pulmonary nodules at diagnosis do not affect outcome in patients with otherwise localized RMS. There is no need to biopsy or upstage patients with RMS who have indeterminate pulmonary nodules at diagnosis.
Subject(s)
Lung Neoplasms/secondary , Multiple Pulmonary Nodules/secondary , Rhabdomyosarcoma/secondary , Soft Tissue Neoplasms/pathology , Solitary Pulmonary Nodule/secondary , Adolescent , Child , Child, Preschool , Europe , Female , Humans , Infant , Infant, Newborn , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/mortality , Lung Neoplasms/therapy , Male , Multiple Pulmonary Nodules/diagnostic imaging , Multiple Pulmonary Nodules/mortality , Multiple Pulmonary Nodules/therapy , Predictive Value of Tests , Progression-Free Survival , Rhabdomyosarcoma/diagnostic imaging , Rhabdomyosarcoma/mortality , Rhabdomyosarcoma/therapy , Risk Factors , Soft Tissue Neoplasms/diagnostic imaging , Soft Tissue Neoplasms/mortality , Soft Tissue Neoplasms/therapy , Solitary Pulmonary Nodule/diagnostic imaging , Solitary Pulmonary Nodule/mortality , Solitary Pulmonary Nodule/therapy , Time Factors , Tomography, X-Ray Computed , Tumor Burden , Young AdultABSTRACT
BACKGROUND AND AIM: We describe a series of three successive patients with perianal rhabdomyosarcoma (PRMS) from 2014 to 2017 managed with combined chemotherapy, radical surgery, and radiotherapy. METHODS: Ethical consent was obtained. Data including tumor presentation, treatment, and survival was collected from hospital reports. RESULTS: Two girls aged 15 and 16â¯years (patient #1 and #2) and one boy aged five years (patient #3) were referred because of a suspected perianal abscess. MRI showed large perianal tumors from 7 to 12â¯cm in diameter that surrounded or infiltrated the anal sphincters and were inconsistent with abscess. Tumor biopsies showed RMS of alveolar (#1 and #2) and embryonal (#3) types. Patient #1 had lymph node and bone metastases, patient #2 lymph node metastases, and patient #3 no metastases. Pretreatment staging, IRS Clinical Group, and Risk Groups were: Stage 4, II, high; Stage 3, GII, intermediate; and Stage 3, I, low, respectively. All underwent colostomy before neoadjuvant chemotherapy (CWS-RMS 2009 program). Neoadjuvant chemotherapy failed to clear the tumors from anal sphincters preventing anus-saving surgery, and all patients underwent abdominoperineal excision. All removed specimens had free margins with negative lymph nodes. After adjuvant chemotherapy and local radiation, the patients were tumor free after 48, 13, and 18â¯months. CONCLUSION: In PRMS local surgical control required abdominoperineal excision. Confusion between PRMS and abscess may cause unnecessary delay in management. LEVEL OF EVIDENCE: IV (Treatment Study, Case Series with no Comparison Group).